Saakshi Medtech

{
  "main_header": {
    "sid": 10039025,
    "name": "Saakshi Medtech",
    "stock_name": "Saakshi Medtech",
    "full_name": "Saakshi Medtech & Panels Ltd",
    "name_url": "stocks-analysis/saakshi-medtech",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "192.00",
    "chg": -1.3,
    "chgp": "-0.67%",
    "dir": -1,
    "prev_price": "193.30",
    "mcapval": "339.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "SAAKSHI",
    "ind_name": "Other Electrical Equipment",
    "ind_code": 8,
    "indexname": "",
    "isin": "INE0PSK01027",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": 205800,
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/saakshi-medtech-10039025-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Saakshi Medtech?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-saakshi-medtech-3704258",
        "imagepath": "",
        "date": "2025-11-15 00:30:47",
        "description": "Answer:\nThe historical performance of Saakshi Medtech shows significant fluctuations in key financial metrics over the years.\n\nBreakdown:\nSaakshi Medtech's net sales have decreased from 122.06 Cr in Mar'23 to 92.43 Cr in Mar'25, reflecting a downward trend. The total operating income followed a similar pattern, dropping from 122.06 Cr in Mar'23 to 92.43 Cr in Mar'25. The raw material costs also decreased from 73.93 Cr in Mar'23 to 58.81 Cr in Mar'25, indicating a reduction in production costs. Operating profit (PBDIT) saw a decline from 20.70 Cr in Mar'23 to 10.88 Cr in Mar'25, with the operating profit margin decreasing from 16.84% to 11.15%. Profit before tax fell from 16.59 Cr in Mar'23 to 6.59 Cr in Mar'25, leading to a profit after tax of 4.71 Cr in Mar'25, down from 12.38 Cr in Mar'23. The company's total assets increased from 93.24 Cr in Mar'23 to 131.10 Cr in Mar'25, while total liabilities also ros..."
      },
      {
        "title": "Is Saakshi Medtech overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-saakshi-medtech-overvalued-or-undervalued-3678261",
        "imagepath": "",
        "date": "2025-11-07 08:14:36",
        "description": "As of 6 November 2025, the valuation grade for Saakshi Medtech has moved from expensive to very expensive. The company is currently overvalued, indicated by a PE ratio of 65.09, an EV to EBITDA ratio of 31.15, and a Price to Book Value of 3.13. In comparison to its peers, Adani Enterprises has a PE ratio of 127.79 and an EV to EBITDA of 29.94, while Tata Chemicals shows a PE of 60.22 and an EV to EBITDA of 16.15, suggesting that Saakshi Medtech's valuation is significantly higher than many of its competitors.\n\nThe company's recent performance has also been underwhelming, with a year-to-date return of -22.64%, contrasting sharply with the Sensex's gain of 7.89% over the same period. This further reinforces the notion that Saakshi Medtech is not only overvalued but also struggling to deliver returns in the current market environment...."
      }
    ],
    "total": 60,
    "sid": "10039025",
    "stock_news_url": "https://www.marketsmojo.com/news/saakshi-medtech-panels-10039025"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Saakshi Medtech?

2025-11-15 00:30:47

Answer: The historical performance of Saakshi Medtech shows significant fluctuations in key financial metrics over the years. Breakdown: Saakshi Medtech's net sales have decreased from 122.06 Cr in Mar'23 to 92.43 Cr in Mar'25, reflecting a downward trend. The total operating income followed a similar pattern, dropping from 122.06 Cr in Mar'23 to 92.43 Cr in Mar'25. The raw material costs also decreased from 73.93 Cr in Mar'23 to 58.81 Cr in Mar'25, indicating a reduction in production costs. Operating profit (PBDIT) saw a decline from 20.70 Cr in Mar'23 to 10.88 Cr in Mar'25, with the operating profit margin decreasing from 16.84% to 11.15%. Profit before tax fell from 16.59 Cr in Mar'23 to 6.59 Cr in Mar'25, leading to a profit after tax of 4.71 Cr in Mar'25, down from 12.38 Cr in Mar'23. The company's total assets increased from 93.24 Cr in Mar'23 to 131.10 Cr in Mar'25, while total liabilities also ros...

Read full news article

Is Saakshi Medtech overvalued or undervalued?

2025-11-07 08:14:36

As of 6 November 2025, the valuation grade for Saakshi Medtech has moved from expensive to very expensive. The company is currently overvalued, indicated by a PE ratio of 65.09, an EV to EBITDA ratio of 31.15, and a Price to Book Value of 3.13. In comparison to its peers, Adani Enterprises has a PE ratio of 127.79 and an EV to EBITDA of 29.94, while Tata Chemicals shows a PE of 60.22 and an EV to EBITDA of 16.15, suggesting that Saakshi Medtech's valuation is significantly higher than many of its competitors. The company's recent performance has also been underwhelming, with a year-to-date return of -22.64%, contrasting sharply with the Sensex's gain of 7.89% over the same period. This further reinforces the notion that Saakshi Medtech is not only overvalued but also struggling to deliver returns in the current market environment....

Read full news article

View All News